Search results
Drug-eluting Balloon Analysis
Author(s):
Alexander Ruebben
,
Juergen Boeing
,
Norbert Weiss
Added:
3 years ago
Article
Drug-eluting Balloon Analysis
Author(s):
Alexander Ruebben
,
Juergen Boeing
,
Norbert Weiss
Added:
3 years ago
Article
Author(s):
Gregg Stone
Added:
3 years ago
Drug-eluting stents (DES) are the standard percutaneous treatment strategy in patients with coronary artery disease (CAD). Their use has further reduced the incidence of restenosis and repeatrevascularisation in single vessel de novo disease. These stents have bioactive coatings that, through a complex mechanism, allow the release of various antiinflammatory and anti-proliferative drugs at high…
View more
Author(s):
Kamal Chitkara
,
Anthony H Gershlick
Added:
3 years ago
First-generation Stents
Since drug-eluting stents (DES) received the CE mark in 2002 and the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. The advent of DES has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for…
View more
Author(s):
Corrado Tamburino
,
Davide Capodanno
Added:
3 years ago
Recently, many eminent scientific journals have published long-term follow-up data from both randomised clinical trials (RCTs) and registries of patients treated with percutaneous coronary intervention (PCI) undergoing drug-eluting stent (DES) implantation. In fact, this is the only course of action to address the concerns regarding DES safety that were first raised almost two years ago.1…
View more
Author(s):
Giulia Magnani
,
Marco Valgimigli
Added:
3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher…
View more
Author(s):
Ferry van der Linde
Added:
3 years ago
Recently, a novel type of interventional device has become available on the market: the drug-eluting balloon (DEB). The established performance of the percutaneous transluminal coronary angioplasty (PTCA) balloon catheter has been combined with the proven efficacy of antiproliferative drugs.
The usefulness of DEBs has been established,1–6 especially for treating in-stent restenosis (ISR), when…
View more
Author(s):
Anouar Belkacemi
,
Pierfrancesco Agostoni
,
Michiel Voskuil
,
et al
Added:
3 years ago
In the past few decades, major progress has been made in the percutaneous treatment of coronary artery disease. Initially, the emergence of balloon angioplasty offered an alternative option for coronary revascularisation. However, abrupt closure and restenosis caused by elastic recoil, neointimal hyperplasia and late remodelling were major drawbacks of balloon angioplasty.1 The use of drug…
View more
Author(s):
Michael Tittelbach
,
Tobias Diener
Added:
3 years ago
Since the introduction of drug-eluting stents (DES), physicians have tried to find a delicate balance between achieving a highly effective result without compromising the safety of the patient. Various concepts have been introduced into the marketplace in the attempt to identify the optimal combination of characteristics; however, until now very little attention has been paid to combining a…
View more
Author(s):
Gaku Nakazawa
,
Masataka Nakano
,
Marc Vorpahl
,
et al
Added:
3 years ago
The limited information regarding the long-term safety of drug-eluting stents (DES) for the treatment of ST-segment-elevation myocardial infarction (STEMI) has raised concern regarding its clinical safety, in particular with respect to the associated morbidity and mortality attributed to late stent thrombosis (LST). Observational studies in daily practice have shown that the risk of LST continues…
View more